Prostate cancer · Oligorecurrent HSPC · 177Lu-PSMA before SBRT
LUNAR
Does neoadjuvant 177Lu-PNT2002 before SBRT improve PFS versus SBRT alone?
Single-centre randomized phase II; 92 randomized, 87 evaluable; 1–5 PSMA-PET lesions. SBRT vs 2 cycles 177Lu-PNT2002 then SBRT.
Trial design
Single-centre randomized phase II; 92 randomized, 87 evaluable; 1–5 PSMA-PET lesions. SBRT vs 2 cycles 177Lu-PNT2002 then SBRT.
Outcome visualization · source-reported data
Median PFS
HR 0.37 (95% CI 0.22–0.61); p<0.0001
Visualization reflects reported outcomes; it does not itself generate an NNT or establish an overall-survival benefit.
Key result
Promising phase II signal for radioligand priming before MDT; single-centre design and follow-up should be considered.
Interpretation and limitations
https://pubmed.ncbi.nlm.nih.gov/41223345/
Primary source
undefined
Read source →